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Commentary
Industrial biotechnology becomes a key com-
petitive factor
At this point the future feedstock market
needs to be discussed. When the chemical
industry enters the agricultural market it will
compete with producers of food, feed, fibers,
rubber, and increasingly bio-energy. Therefo-
re the chemical industry is eager to explore
alternatives to agricultural feedstock like ligno-
cellulosic agricultural waste and wood. Provi-
ding commercial solutions in this field is anot-
her common and urgent challenge to acade-
mic and industrial process development.
Incorporating the perspective of the Euro-
pean chemical industry regarding the compe-
titive availability of renewable feedstock is of
particular relevance. With Europe’s limited
agricultural area its industry will largely
depend on imports from countries and regi-
ons, such as the US, Brazil, South-East Asia and
Russia (King & Hagan, 2010). When the futu-
re trend of producing bulk precursors from
renewable carbon sources for chemical appli-
cations is gaining momentum, such producti-
on units may be most competitive in those
regions. Therefore, European chemical sites,
with no renewable carbon resources nearby,
are forced to focus continuously on the com-
petitiveness of their processes and a sustai-
ned pipeline of value-adding products. In some
way industrial biotechnology is an innovati-
on driver itself: the more successfully it achie-
ves industrial transformation of renewable
feedstock, the more it becomes a critical com-
petitive factor.
Establishing industrial biotechnology is an
extremely complex issue. Numerous hurdles
need to be overcome. Questions of science (syn-
thetic biology), technology (integration of bio-
tech- and synthetic process steps), feedstock
availability (infrastructure), politics (legisla-
tive framework), training (academic and tech-
nical staff) and public acceptance need to be
answered. However, the biggest challengemay
Industrial biotechnology is established since
decades in producing diverse products such as
enzymes, amino acids, enantiomerically pure
pharma-actives and more (Haas et al., 2010).
However, in spite of these successful exam-
ples biotechnology still plays a minor role in
the chemical industry, accounting for only
3-6% of the global sales volume. It is more or
less only successful in those niches where
petro-chemistry does not work: enzymes and
enantiomerically pure products are simply not
available by chemical synthesis. This limita-
tion is going to be cleared away through
modern biotechnology. Beside the products
already mentioned before, non-natural che-
micals will be also available. They will be the
future precursors in procedures combining
biotechnology and chemical synthesis.
Bio-/chemical processes will be the cruci-
al building block of the future production sys-
tem sweeping the entire industry. It is the visi-
on of an industry predominantly based on raw
materials, which recycles auxiliary and end
products. A core element of this vision, as una-
nimously supported by the European Union
as Knowledge-Based Bio-Economy (KBBE) and
by the German government as BioÖkonomie,
is industrial biotechnology (Research DG, 2005;
King & Hagan, 2010). Accelerating this deve-
lopment needs more joint and strong efforts
of industry and academia in pushing the
recently emerging synthetic biotechnology,
improving continuous processes, reducing
downstream processing costs and integrating
biotechnological and synthetic process steps.
While reaching commercial success through
early R&D is not guaranteed, public support
is necessary and already given. However, public
funding should take even more consideration
of industrial relevance, including projects that
are close to the commercialization stage, such
as pilot plants.
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arise from the development of a new, agricul-
tural and silvicultural value chain reaching
from feedstock- and biochemical transforma-
tion to consumer industries (Figure 1, Kircher,
2006).
It is obvious that walking this way alone is
too challenging even for big companies. To be
successful, industries need access to scienti-
fic, technical and business competencies in all
steps of the value chain. Therefore, in Germa-
ny the cluster CLIB2021, (Cluster industrielle
Biotechnologie 2021 e.V.), supported by the Ger-
man Federal Ministry of Education and
Research (BMBF) and the Ministry of Innova-
tion, Science and Research of the German state
of NRW (MIWF), has been founded.
Today this type of cluster-forming is wide-
ly perceived to be most promising in paving
the way to the KBBE. Recently, the European
Commission acknowledged 3 European clus-
ters as role models: the Bio-Hub in France, the
BE-Basic in the Netherlands and the CLIB2021
in Germany (Research DG, 2005). Through part-
nering along the biotechnological value chain,
such organized clusters are crucial in winning
the global competition in industrial biotech-
nology. All academic, industrial and financing
stakeholders should join. The time is right now!
Figure 1 The value chain of industrial biotechnology
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